MOTS-c vs SS-31: Mitochondrial Peptides Head-to-Head

NorthPeptide Research Team  |  April 13, 2026

Introduction: Two Roads Into the Mitochondria

Mitochondria are not passive organelles. They signal, adapt, and respond — and when they fail, the consequences cascade across nearly every tissue in the body. Age-related mitochondrial dysfunction is now listed among the core hallmarks of aging, and it underpins conditions ranging from heart failure and metabolic syndrome to neurodegeneration and sarcopenia.

Two peptides have emerged as leading research tools for interrogating mitochondrial biology: MOTS-c, a 16-amino-acid peptide encoded within the mitochondrial genome itself, and SS-31 (elamipretide), a synthetic tetrapeptide rationally designed to concentrate inside the inner mitochondrial membrane. Both compounds target mitochondrial function — but from entirely different entry points, through distinct mechanisms, and with meaningfully different clinical data profiles.

This comparison examines the science behind each peptide, where the research evidence is strongest, and how they differ in ways that matter for study design.

Origins and Structure: As Different as They Get

MOTS-c: From the Mitochondrial Genome

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) was described in 2015 by Changhan David Lee and Pinchas Cohen at the University of Southern California, who found it encoded within the 12S rRNA gene of mitochondrial DNA — a region not previously thought to contain protein-coding sequences. Its 16-amino-acid sequence (MRWQEMGYIFYPRKLR) is produced by the mitochondrial genome itself and detected as a circulating peptide in human plasma.

This makes MOTS-c a mitochondrial-derived peptide (MDP) — one of a small family of signaling molecules now understood to function as retrograde communicators, carrying information from mitochondria back to the nucleus and into systemic circulation. Exercise raises MOTS-c expression in human skeletal muscle and in circulation, which is the observation the "exercise mimetic" framing rests on. Whether circulating MOTS-c declines with age in humans is not established, and one controlled trial found plasma mitochondrial-derived peptide levels unrelated to fitness status — so treat MOTS-c as a candidate biomarker rather than a validated one.

SS-31: A Rationally Designed Mitochondrial Membrane Peptide

SS-31 (D-Arg-Dmt-Lys-Phe-NH₂), developed by Dr. Hazel Szeto at Weill Cornell Medical College with the peptide chemist Dr. Peter Schiller, is entirely synthetic. It was not discovered in biology — it was engineered. Its alternating aromatic-cationic motif drives rapid, selective concentration in the inner mitochondrial membrane — roughly 1,000-fold over the cytosol — independent of membrane potential. This is a critical design feature: most mitochondria-targeted compounds rely on membrane potential and fail in dysfunctional mitochondria where that potential is compromised. SS-31 accumulates regardless.

Pharmaceutical names for SS-31 include elamipretide (current), Bendavia, and MTP-131. Clinical development has been conducted by Stealth BioTherapeutics, which remains the sponsor; in September 2025 the FDA granted elamipretide accelerated approval, under the brand name Forzinity, to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

Mechanism of Action: The Core Difference

How MOTS-c Works

MOTS-c inhibits specific enzymes in the folate-methionine cycle, causing AICAR to accumulate intracellularly. AICAR is a well-characterized endogenous AMPK activator — the same pathway engaged during aerobic exercise. AMPK activation then drives downstream effects including enhanced glucose uptake via GLUT4 translocation, fatty acid oxidation, mitochondrial biogenesis via PGC-1α, and autophagy induction.

Under metabolic stress, MOTS-c also translocates to the nucleus, where it interacts with transcription factors to upregulate antioxidant response element (ARE)-dependent genes. This retrograde nuclear signaling is one of the most biologically remarkable features of any peptide currently under investigation.

How SS-31 Works

SS-31 binds cardiolipin — the phospholipid found exclusively in the inner mitochondrial membrane that is essential for the structural integrity of electron transport chain supercomplexes. Cardiolipin maintains the organization of complexes I, III, IV, and V into respirasomes that enable efficient electron transfer. When cardiolipin is oxidized or depleted (by ROS, disease, or aging), this supercomplex architecture collapses, electron leak increases, more ROS is generated, and the cycle accelerates.

SS-31 breaks this cycle at its source. By stabilizing cardiolipin, it preserves supercomplex organization, reduces electron leak, improves ATP output per oxygen consumed, and prevents cytochrome c from gaining peroxidase activity that would further damage cardiolipin. It also inhibits the mitochondrial permeability transition pore (mPTP), reducing ischemia-reperfusion injury.

Preclinical Research: Where Each Peptide Has the Most Data

MOTS-c: Metabolic Disease, Aging, Bone

The original 2015 discovery paper in Cell Metabolism established MOTS-c as a metabolic regulator in mouse models: 0.5 mg/kg/day intraperitoneally for eight weeks prevented diet-induced obesity and both age-dependent and high-fat-diet-induced insulin resistance. A 2021 Nature Communications study extended this to physical function — MOTS-c improved running capacity in young (2 mo), middle-aged (12 mo) and old (22 mo) mice, and treatment started late in life (~23.5 mo, 15 mg/kg three times weekly) increased physical capacity and healthspan.

On bone, the evidence is a single mouse study and it points in a direction often misreported. A 2016 paper in Biochemical and Biophysical Research Communications found that 5 mg/kg/day of MOTS-c for 12 weeks reduced ovariectomy-induced bone loss in mice, measured by micro-CT. The mechanism was inhibition of RANKL-driven osteoclast differentiation via AMPK — an anti-resorptive effect, not stimulation of osteoblasts, and bone mineral density itself was not the endpoint. Separate in vitro work has reported that MOTS-c promotes osteogenic differentiation of cultured rat marrow stromal cells through TGF-β/Smad signaling (Hu 2018), but that is cell-culture evidence — the ovariectomy study did not test bone formation as an in vivo endpoint.

Human evidence exists, and it is thinner than it is usually made to sound. In the 2021 Nature Communications study above, stationary cycling in young sedentary men raised skeletal-muscle MOTS-c roughly 12-fold and circulating MOTS-c about 1.6-fold, with plasma levels back at baseline four hours later. A separate randomized trial published in the Journal of Applied Physiology in 2021 found that acute endurance exercise moved plasma MOTS-c only as a non-significant trend, that acute resistance exercise did not move it at all, and that circulating mitochondrial-derived peptide levels were not related to fitness status. Exercise induces MOTS-c; "trained people carry more MOTS-c" is not currently supported.

A genetic observation is often cited here, and it cuts both ways. The Northeast-Asian mtDNA variant m.1382A>C substitutes glutamine for lysine at position 14 of MOTS-c (K14Q), and a 2015 Aging Cell commentary proposed it as one candidate mechanism behind Japanese longevity. That piece was a hypothesis paper — it reported no genotyping of its own. When the variant was characterized functionally, in a 2021 meta-analysis of three cohorts (n = 27,527), men carrying the C allele showed a higher prevalence of type 2 diabetes, and K14Q-MOTS-c was less insulin-sensitizing than wild-type peptide in vitro and failed to improve glucose tolerance in high-fat-fed male mice. The longevity link remains an open hypothesis; the metabolic finding points the other way.

SS-31: Cardiac Disease, Mitochondrial Myopathy, Renal and Neurological Models

SS-31's deepest evidence base is in cardiac and mitochondrial disease models. Three months of daily subcutaneous elamipretide (0.5 mg/kg) raised ejection fraction, normalized NT-proBNP and inflammatory markers, and restored mitochondrial respiration, membrane potential and ATP synthesis in a 14-dog model of advanced heart failure. In pressure-overload heart failure in mice, SS-31 attenuated roughly 84% of the disease's mitochondrial proteome remodeling and blunted the heart failure phenotype. And in explanted failing human ventricular tissue treated ex vivo, elamipretide improved mitochondrial oxygen flux, complex I and complex IV activity, and supercomplex-associated complex IV activity. Note what these studies actually measured — mitochondrial function and bioenergetics, not cardiolipin content or fibrosis directly. In ischemia-reperfusion models, SS-31 accelerated ATP recovery and reduced injury in ischemic rat kidney, and improved contractile recovery in the ex vivo ischemic heart.

The aging data comes from two studies, and they answer different questions. In eLife (2020), eight weeks of SS-31 at 3 mg/kg/day by subcutaneous osmotic minipump substantially reversed diastolic dysfunction in 24-month-old mice, normalized the age-related rise in mitochondrial proton leak and reduced cardiomyocyte ROS — but that study did not measure cardiolipin content or electron transport chain complex activity. In Aging Cell (2013), a single 3 mg/kg intraperitoneal dose restored resting and maximal mitochondrial ATP production and oxidative-phosphorylation coupling in aged mouse skeletal muscle to young levels within one hour, and eight days of treatment increased whole-animal endurance capacity.

In neurodegenerative models, SS-31 gave dose-dependent protection against striatal dopamine loss and loss of tyrosine-hydroxylase-positive neurons in the MPTP mouse model of Parkinson's, reduced amyloid-associated mitochondrial and synaptic damage in Alzheimer's cell and mouse models, and improved survival and motor performance in G93A SOD1 mice, a model of ALS.

Clinical Data: SS-31 Has the Advantage

This is the most important differentiator between the two peptides from an evidence standpoint.

MOTS-c: No clinical trial administering MOTS-c to humans has been published. All efficacy data is preclinical. The human exercise data establishes that endogenous MOTS-c responds to physical activity — a biomarker observation, not evidence that administering the peptide does anything in people. No human safety or dose-finding data exists.

SS-31: Has completed multiple phase II clinical trials. Most of them missed their primary endpoints, which is the part usually left out:

• EMBRACE STEMI — Phase 2a randomized, double-blind, placebo-controlled trial of intravenous MTP-131 (0.05 mg/kg/h for one hour) in first-time anterior ST-elevation myocardial infarction during primary percutaneous coronary intervention. It did not meet its primary endpoint: infarct size by CK-MB area under the curve over 72 hours was unchanged, and no pre-specified MRI, angiographic, electrocardiographic or clinical outcome improved. It was safe and well tolerated.
• HFrEF, single infusion (n = 36) — A double-blind, placebo-controlled ascending-dose trial gave a single four-hour intravenous infusion of elamipretide to 24 patients with ejection fraction ≤35%, against 12 placebo controls. At the highest dose, echocardiography showed reductions in left ventricular end-diastolic (−18 mL) and end-systolic (−14 mL) volume at end of infusion. This is a single-infusion pharmacodynamic signal, not a treatment course.
• PROGRESS-HF (n = 71) — The follow-up randomized, double-blind, placebo-controlled trial gave 4 mg or 40 mg of subcutaneous elamipretide daily for 28 days and measured left ventricular end-systolic volume by cardiac MRI. It did not improve end-systolic volume or ejection fraction versus placebo at four weeks. The drug was well tolerated.
• TAZPOWER (Barth syndrome) — A randomized, double-blind, placebo-controlled crossover trial in Barth syndrome, a rare genetic disorder defined by defective cardiolipin remodeling: 12 subjects took 40 mg/day of elamipretide or placebo for 12 weeks each, separated by a four-week washout. Neither primary endpoint was met in the randomized phase. Ten subjects continued into an open-label extension, and at 36 weeks there were significant improvements in the 6-minute walk test (+95.9 m) and the Barth Syndrome Symptom Assessment (−2.1 points), plus knee extensor strength and some cardiac parameters. An open-label extension has no control arm, so those gains carry a weaker evidence grade than the failed randomized phase — but they were the basis for the September 2025 FDA accelerated approval, and this remains the most direct clinical test of the cardiolipin hypothesis.
• ReCLAIM-2 (dry age-related macular degeneration) — Phase II randomized, placebo-controlled, double-masked trial; 176 patients on 40 mg subcutaneous daily for 48 weeks. Both primary endpoints were missed (change in low-luminance best-corrected visual acuity and change in geographic atrophy area). Additional pre-defined endpoints moved at nominal significance: a 43% reduction in progression of complete ellipsoid zone loss, and more patients gaining ≥10 letters of low-luminance acuity (14.6% vs 2.1%).
• MMPOWER (primary mitochondrial myopathy) — Phase I/II randomized, double-blind, placebo-controlled dose-escalation trial in 36 patients with genetically confirmed disease, given intravenous elamipretide over two hours in ascending doses. Distance walked on the 6-minute walk test rose dose-dependently; the highest dose versus placebo was borderline unadjusted (p = 0.053) and significant after covariate adjustment (p = 0.0297). No other efficacy or safety endpoint differed.

Dose-escalation work has established human pharmacokinetics and a workable safety profile with no reported dose-limiting toxicity. This clinical data package is unusual for a compound also sold as a research peptide — but read it for what it shows: consistent tolerability, a real functional signal in one ultra-rare cardiolipin-remodeling disorder, and repeated failures on hard primary endpoints in the common cardiovascular and ophthalmic indications.

Safety Profiles

MOTS-c

Published mouse studies have used 0.5–15 mg/kg intraperitoneally for up to 12 weeks without reporting significant adverse effects — but none of them was designed as a toxicology study, so absence of reported harm is not the same as a safety finding. As an endogenous human peptide produced from the mitochondrial genome, it is metabolized through normal pathways. No human safety data exists.

SS-31

Human safety data across the trial programme is consistent: elamipretide has been well tolerated at every dose tested, with no dose-limiting toxicity reported. Injection site reactions with subcutaneous dosing are not trivial, though — in ReCLAIM-2, 86% of the elamipretide group reported an adverse event against 71% on placebo, with injection site pruritus, pain, bruising and erythema the most common. The therapeutic window is favorable in the sense that matters mechanistically: this peptide class concentrates roughly 1,000-fold in the inner mitochondrial membrane relative to the cytosol, so low systemic doses reach a meaningful mitochondrial concentration.

Dosing in Research Models

Research Application Summary: Which to Use and When

Are They Complementary?

The mechanistic answer is yes — but the research to support combination protocols is essentially absent. MOTS-c acts upstream of mitochondrial function, reprogramming metabolism and signaling for energy optimization. SS-31 acts at the membrane level, protecting the physical machinery of electron transport from oxidative damage. These are not redundant pathways.

No published study has tested MOTS-c and SS-31 together, in any model. The logic is coherent: you could theoretically drive mitochondrial biogenesis and metabolic reprogramming via MOTS-c (and NAD+ precursors), while simultaneously protecting the existing mitochondrial machinery via SS-31. But coherent logic is not data — whether this yields additive, synergistic, or no effects is an open experimental question, and nothing on this page should be read as suggesting the answer is known.

PubMed Citations

1. Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. PMID: 25738459
2. Kim KH, Son JM, Benayoun BA, Lee C. "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress." Cell Metabolism. 2018;28(3):516-524.e7. PMID: 29983246
3. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications. 2021;12(1):470. PMID: 33473109
4. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. "Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans." Journal of Applied Physiology. 2021;131(3):1035-1042. PMID: 34351816
5. Ming W, Lu G, Xin S, et al. "Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation." Biochemical and Biophysical Research Communications. 2016;476(4):412-419. PMID: 27237975
6. Hu BT, Chen WZ. "MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway." European Review for Medical and Pharmacological Sciences. 2018;22(21):7156-7163. (Cultured rat BMSCs only — no in vivo arm.) PMID: 30468456
7. Fuku N, Pareja-Galeano H, Zempo H, et al. "The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" Aging Cell. 2015;14(6):921-923. (Hypothesis/commentary — reports no genotyping of its own.) PMID: 26289118
8. Zempo H, Kim SJ, Fuku N, et al. "A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c." Aging (Albany NY). 2021;13(2):1692-1717. PMID: 33468709
9. Zhao K, Zhao GM, Wu D, et al. "Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury." Journal of Biological Chemistry. 2004;279(33):34682-34690. PMID: 15178689
10. Szeto HH. "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology. 2014;171(8):2029-2050. PMID: 24117165
11. Dai DF, Hsieh EJ, Chen T, et al. "Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides." Circulation: Heart Failure. 2013;6(5):1067-1076. PMID: 23935006
12. Sabbah HN, Gupta RC, Kohli S, et al. "Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure." Circulation: Heart Failure. 2016;9(2):e002206. PMID: 26839394
13. Chatfield KC, Sparagna GC, Chau S, et al. "Elamipretide improves mitochondrial function in the failing human heart." JACC: Basic to Translational Science. 2019;4(2):147-157. (Ex vivo treatment of explanted human myocardium, not a clinical trial.) PMID: 31061916
14. Chiao YA, Zhang H, Sweetwyne M, et al. "Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice." eLife. 2020;9:e55513. PMID: 32648542
15. Siegel MP, Kruse SE, Percival JM, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-771. PMID: 23692570
16. Szeto HH, Liu S, Soong Y, et al. "Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury." Journal of the American Society of Nephrology. 2011;22(6):1041-1052. PMID: 21546574
17. Yang L, Zhao K, Calingasan NY, et al. "Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity." Antioxidants & Redox Signaling. 2009;11(9):2095-2104. PMID: 19203217
18. Reddy PH, Manczak M, Kandimalla R. "Mitochondria-targeted small molecule SS31: a potential candidate for the treatment of Alzheimer's disease." Human Molecular Genetics. 2017;26(8):1483-1496. PMID: 28186562
19. Petri S, Kiaei M, Damiano M, et al. "Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis." Journal of Neurochemistry. 2006;98(4):1141-1148. PMID: 16895581
20. Gibson CM, Giugliano RP, Kloner RA, et al. "EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention." European Heart Journal. 2016;37(16):1296-1303. (Primary endpoint not met.) PMID: 26586786
21. Daubert MA, Yow E, Dunn G, et al. "Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide." Circulation: Heart Failure. 2017;10(12):e004389. (Single four-hour IV infusion, n = 36.) PMID: 29217757
22. Butler J, Khan MS, Anker SD, et al. "Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial." Journal of Cardiac Failure. 2020;26(5):429-437. (Primary endpoint not met.) PMID: 32068002
23. Reid Thompson W, Hornby B, Manuel R, et al. "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism." Genetics in Medicine. 2021;23(3):471-478. (TAZPOWER — neither primary endpoint met in the randomized crossover phase; improvements reported at 36 weeks of the open-label extension.) PMID: 33077895
24. Ehlers JP, Hu A, Boyer D, et al. "ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation." Ophthalmology Science. 2025;5(1):100628. (Both primary endpoints not met.) PMID: 39605874
25. Karaa A, Haas R, Goldstein A, et al. "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy." Neurology. 2018;90(14):e1212-e1221. PMID: 29500292
26. Shirley M. "Elamipretide: first approval." Drugs. 2026;86(3):377-383. PMID: 41335372